4539.T
NIPPON CHEMIPHAR CO.,LTD.
スタンダード · 医薬品 · 医薬品 · JP
JPY 1,569.00
−1.94%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 32.5B | 33.1B | 32.6B | 30.7B | 31.6B |
| Cost of Revenue | 6.0B | 24.7B | 23.8B | 23.0B | 23.4B |
| Gross Profit | 2.3B | 8.4B | 8.7B | 7.7B | 8.2B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 2.0B | 8.2B | 8.1B | 8.2B | 8.4B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 2.0B | 8.2B | 8.1B | 8.2B | 8.4B |
| Cost and Expenses | 32.1B | 32.9B | 32.0B | 31.2B | 31.8B |
| Operating Income (EBIT) | 458.0M | 179.0M | 606.0M | (494.0M) | (241.0M) |
| Non-Operating | |||||
| Interest Income | 3.0M | 10.0M | 5.0M | 3.0M | 2.0M |
| Interest Expense | 52.0M | 225.0M | 198.0M | 150.0M | 122.0M |
| Net Interest Income | (49.0M) | (215.0M) | (193.0M) | (147.0M) | (120.0M) |
| Other Non-Op Income/Expense | (84.0M) | 48.0M | (163.0M) | 275.0M | 300.0M |
| Non-Operating Income (excl Interest) | 69.0M | 300.0M | 101.0M | 446.0M | 473.0M |
| EBT (Pre-Tax Income) | 305.0M | 221.0M | 253.0M | (202.0M) | 480.0M |
| Income Tax Expense | 78.0M | 23.0M | (41.0M) | (21.0M) | 141.0M |
| Bottom Line | |||||
| Net Income | 545.0M | 198.0M | 294.0M | (180.0M) | 339.0M |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 545.0M | 198.0M | 294.0M | (180.0M) | 339.0M |
| Per Share | |||||
| Basic EPS | ¥151 | ¥55 | ¥82 | (¥50) | ¥94 |
| Diluted EPS | ¥151 | ¥55 | — | — | — |
| Revenue Per Share | ¥9,009 | ¥9,157 | ¥9,027 | ¥8,520 | ¥8,744 |
| Shares | |||||
| Basic Shares Outstanding | 3.6M | 3.6M | 3.6M | 3.6M | 3.6M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | 1.7B | 2.0B | 965.0M | 1.3B |
| D&A | — | 1.6B | 1.4B | 1.5B | 1.5B |
| EBIT | 458.0M | 179.0M | 606.0M | (494.0M) | (241.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026